IP Library › Granted Patent US 11,071,585
Granted Patent B2
US 11,071,585 · App. 16/569,608 · Granted Jul 27, 2021

Systems and methods of ablating cardiac tissue

Inventors: Xiangming Zhang (Irvine, CA); Nader Ghaly (Irvine, CA); Eid Adawi (Tur'an, IL); Moe Habib Bishara (Irvine, CA); Kendra Anita McInnis (Irvine, CA); Assaf Govari (Haifa, IL); Christopher Thomas Beeckler (Brea, CA); Joseph Thomas Keyes (Sierra Madre, CA); Rowan Olund Hettel (Irvine, CA); Kevin Justin Herrera (West Covina, CA)
Assignee: Biosense Webster (Israel) Ltd.
A61B18/1492A61B18/1206A61M25/10A61B2018/00351A61B2018/00375A61B2018/00577A61B2018/00755A61B2018/00791A61B2018/1417A61M2025/1079
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,071,585
App. No.
16/569,608
Granted
Jul 27, 2021
Kind
B2
Abstract

The subject of this disclosure includes systems, devices and methods to treat a predetermined patient population for paroxysmal atrial fibrillation, the method including ablating tissue of one or more targeted pulmonary veins with one or more of a plurality of the electrodes of an independently controlled multi-electrode radiofrequency balloon catheter, the balloon catheter comprising the plurality of electrodes for radiofrequency ablation that are independently controllable; determining a predictor, based on ablation parameters of the balloon catheter, of single shot pulmonary vein isolation (PVI) success rate; and achieving, based on the predictor and step of ablating tissue, a single shot isolation PVI success rate in the isolation of all targeted pulmonary veins for the predetermined patient population.

Claims (14)

1. A method to treat a predetermined patient population for paroxysmal atrial fibrillation, the method comprising:

ablating tissue of one or more targeted pulmonary veins with one or more of a plurality of electrodes of a radiofrequency balloon catheter;

determining a characteristic, based on ablation parameters of the radiofrequency balloon catheter, of single shot pulmonary vein isolation (PVI) success rate; and

achieving, based on the characteristic and step of ablating the tissue, a single shot isolation PVI success rate in an isolation of all targeted pulmonary veins for the predetermined patient population.

2. The method of claim 1 , wherein the step of achieving the single shot isolation PVI success rate further comprises achieving at least about a 91.7% success rate by ablating with a pre-ablation mean initial impedance of less than about 95Ω.

3. The method of claim 1 , wherein the step of achieving the single shot isolation PVI success rate further comprises achieving at least about 88% success rate by ablating with a pre-ablation highest initial anterior wall impedance of about 110Ω.

4. The method of claim 1 , wherein the step of achieving the single shot isolation PVI success rate further comprises achieving at least about 87.5% success rate by ablating with a pre-ablation initial anterior wall impedance variation impedance range of less than about 20Ω.

5. The method of claim 1 , wherein the characteristic is a predictor of the single shot isolation PVI success rate before ablation was limiting a highest initial temperature to less than about 31° C. among the plurality of electrodes of the balloon catheter.

6. The method of claim 1 , wherein the step of achieving the single shot isolation PVI success rate further comprises achieving at least about a 90% success rate by ablating with a mean initial impedance of less than about 95Ω for and a highest initial impedance of less than about 110Ω.

7. The method of claim 1 , wherein the characteristic is a predictor of the single shot isolation PVI success rate before ablation, the predictor being mean initial temperature, and wherein the mean initial temperature is approximately less than about 28° C. and the single shot isolation PVI success rate is at least approximately about 90%.

8. The method of claim 1 , wherein the characteristic is a predictor of the single shot isolation PVI success rate before ablation, the predictor being a pre-ablation lowest temperature slope, and wherein the pre-ablation lowest temperature slope is approximately greater than about 0.75° C./sec, and the single shot isolation PVI success rate is at least approximately about 90%.

9. The method of claim 1 , wherein the characteristic is a predictor of the single shot isolation PVI success rate before ablation, the predictor being a pre-ablation lowest value temperature, and wherein the pre-ablation lowest value temperature is approximately greater than about 6° C., and the single shot isolation PVI success rate is at least approximately about 90%.

10. The method of claim 1 , wherein the characteristic is a predictor of the single shot isolation PVI success rate before ablation, the predictor being a pre-ablation initial impedance variation, and wherein the pre-ablation initial impedance variation comprises an optimal range of approximately less than about 20Ω, and the single shot isolation PVI success rate is at least approximately about 88.5%.

11. The method of claim 1 , wherein when one or more of the plurality of electrodes with initial impedance deviation from mean value is zero, the single shot isolation PVI success rate is approximately about 92%.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2020
From: ZHANG, XIANGMING; GHALY, NADER; ADAWI, EID; BISHARA, MOE HABIB; MCINNIS, KENDRA ANITA; GOVARI, ASSAF; BEECKLER, CHRISTOPHER THOMAS; KEYES, JOSEPH THOMAS; HETTEL, ROWAN OLUND; HERRERA, KEVIN JUSTIN
To: BIOSENSE WEBSTER (ISRAEL) LTD.
Reel/Frame 052959/0364 →
Continuity (7)
Provisional Application 62731525 · Sep 14, 2018
Provisional Application 62754275 · Nov 1, 2018
Provisional Application 62771896 · Nov 27, 2018
Provisional Application 62886729 · Aug 14, 2019
Provisional Application 62889471 · Aug 20, 2019
Provisional Application 62873636 · Jul 12, 2019
Related Publication 20200085497A1 · Mar 19, 2020
Cited By (17)
US 12,201,354 US 12,262,943 US 12,290,310 US 12,376,879 US 12,440,263 US 12,446,946 US 12,471,989 US 12,478,424 US 12,484,961 US 12,533,185 US 12,648,811 US 12,661,737 US 12,667,415 US 12,667,712 US 12,708,438 US 12,721,676 US 12,746,059